Polar Capital reports 8.47% stake in ENLIVEN THERAPEUTICS

Polar Capital group reports holding 5,065,933 shares (Common Stock) of ENLIVEN THERAPEUTICS, INC.

Rhea-AI Filing Summary

Polar Capital group reports holding 5,065,933 shares (Common Stock) of ENLIVEN THERAPEUTICS, INC. The filing amends a prior Schedule 13G and states this equals 8.47% of the class based on 60,904,946 shares outstanding as of May 7, 2026.

The disclosure lists Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund as joint filers, with sole voting and dispositive power over the reported shares. The amendment is signed by Nicholas Farren, Chief Operating Officer, on behalf of the reporting entities.

Insights

Institutional Ownership Analyst

Large passive stake disclosed: 5,065,933 shares, 8.47% ownership.

The Schedule 13G/A amendment records an 8.47% beneficial ownership position held jointly by Polar Capital-related entities. The filing attributes sole voting and dispositive power of 5,065,933 shares to the reporting persons and references May 7, 2026 for the outstanding share base.

Because this is a 13G-style disclosure, it indicates an institutional investor position rather than an active takeover bid. Subsequent filings would show any change in ownership or voting intent.

Governance & Compliance Specialist

Joint filing and signature structure aligns with Rule 13d-1(k) joint filing mechanics.

The exhibit includes a Joint Filing Statement under Rule 13d-1(k), confirming the three Polar Capital entities are filing jointly and accept responsibility for amendments. The signature block shows Nicholas Farren signing as Chief Operating Officer for each entity.

Investors can treat this as an institutional disclosure of beneficial ownership; any change in intent would require an updated Schedule 13D/A or 13G/A amendment.

Key Figures

Beneficial ownership: 5,065,933 shares Percent of class: 8.47% Shares outstanding: 60,904,946 shares

3 metrics

Beneficial ownership 5,065,933 shares Amount beneficially owned reported in Schedule 13G/A

Percent of class 8.47% Percent of class based on outstanding shares

Shares outstanding 60,904,946 shares Shares outstanding as reported in issuer's Form 10-Q on May 7, 2026

Key Terms

Schedule 13G/A, Beneficially owned, Joint Filing Statement

3 terms

Schedule 13G/A regulatory

"The filing is titled SCHEDULE 13G/A and amends a prior statement"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4. Ownership (a) Amount beneficially owned: 5,065,933"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Joint Filing Statement regulatory

"Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Polar Capital report in ENLIVEN THERAPEUTICS (ELVN)?

Polar Capital reports beneficial ownership of 5,065,933 shares, equal to 8.47% of the class. This percentage is calculated using 60,904,946 shares outstanding as of May 7, 2026, as cited in the filing.

Which Polar Capital entities filed the Schedule 13G/A for ELVN?

The filing lists Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund as joint filers. The exhibit includes a joint filing statement under Rule 13d-1(k) signed by Nicholas Farren.

Does the filing indicate who controls voting and disposition of the shares?

Yes. The Schedule shows the reporting persons have sole voting power and sole dispositive power over 5,065,933 shares. Shared voting and dispositive powers are reported as 0 in the amendment.

What is the filing date and who signed the amendment for ELVN?

The amendment is signed by Nicholas Farren, Chief Operating Officer, on behalf of the reporting entities. The signature date shown in the extract is 05/15/2026 on the amendment cover pages.

Is this Schedule 13G/A indicative of an activist intent by Polar Capital?

A Schedule 13G/A typically indicates an institutional passive investor disclosure rather than activist intent. The document includes a joint filing statement; no language in the excerpt asserts a change in voting intent or activist objectives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 09:12 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ENLIVEN THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

29337E102

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 29337E102

1

Names of Reporting Persons

Polar Capital Holdings Plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 59,800,406.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 59,800,406.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

59,800,406.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.47 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 29337E102

1

Names of Reporting Persons

Polar Capital LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 59,800,406.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 59,800,406.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

59,800,406.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.47 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 29337E102

1

Names of Reporting Persons

Polar Capital Funds PLC - Biotechnology Fund

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 59,800,406.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 59,800,406.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

59,800,406.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.47 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ENLIVEN THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 6200 Lookout Road, Boulder, CO 80301
Item 2.
(a)	Name of person filing: Polar Capital Holdings Plc Polar Capital LLP Polar Capital Funds PLC - Biotechnology Fund
(b)	Address or principal business office or, if none, residence: 16 Palace Street London, SW1E 5JD George's Court, 54-62 Townsend Street Dublin 2, Ireland
(c)	Citizenship: United Kingdom
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 29337E102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,065,933
(b)	Percent of class: 8.47%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5,065,933
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5,065,933
	(iv) Shared power to dispose or to direct the disposition of: 0 Based on 60,904,946 shares outstanding as reported in the Issuer's Form 10-Q on May 7, 2026.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Information for each Subsidiary is incorporated on the respective cover pages.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Polar Capital Holdings Plc

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	05/15/2026

Polar Capital LLP

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	05/15/2026

Polar Capital Funds PLC - Biotechnology Fund

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	05/15/2026

Exhibit Information

Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Polar Capital Holdings PLC By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital LLP By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital Funds PLC - Biotechnology Fund By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer